Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 6, November-December, p. 933–938

Publication type: original article

Language: English

Serum and Urinary MIP-1α and IP-10 Levels in Children with Urinary Tract Infections

Daiva Gorczyca1,A,B,C,D,E,F, Daria Augustyniak2,A,B,C,D,F, Barbara Basiewicz-Worsztynowicz1,A,B,D,F, Wiesława Karnas-Kalemba1,A,B,C,F

1 3rd Department and Clinic of Pediatrics, Immunology and Rheumatology of Developmental Age, Wroclaw Medical University, Poland

2 Department of Pathogen Biology and Immunology, Institute of Genetics and Microbiology, Wroclaw Medical University, Poland


Objectives. Urinary tract infection (UTI) is a common bacterial disease in infants and children, with potentially serious complications, including kidney damage. The aim of this study was to test whether serum and urinary levels of interleukin-6 (IL-6), macrophage inflammatory protein-1α (MIP-1α) and interferon-γ-inducible protein-10 (IP-10) can be used as biomarkers in children with urinary tract infections.
Material and Methods. The study group consisted of 22 children with UTI and 20 controls. Blood and urine samples were collected in the acute phase and the convalescent phase, on the eighth day after the onset of antibiotic therapy. Serum and urine levels of MIP-1α, IP-10 and IL-6 were measured.
Results. In children with UTI in the acute phase, serum MIP-1α and IL-6 levels were significantly higher compared to the controls (p < 0.05 and p < 0.005, respectively). A correlation between the serum levels of the chemokines MIP-1α and IP-10 in the acute phase was found.
Conclusion. The findings suggest that the chemokines MIP-1α or IP-10 respond to infection, but they cannot be used as biomarkers for UTI in childhood.

Key words

chemokines, children, urinary tract infection.

References (28)

  1. Slater M, Krug SE: Evaluation of the infant with fever without source: an evidence based approach. Emerg Med Clin North Am 1999, 17, 97–126.
  2. Mori R, Lakhanpaul M, Verrier-Jones K: Diagnosis and management of urinary tract infection in children: summary of NICE guidance. BMJ 2007, 335, 395–397.
  3. Madsen MG, Nørregaard R, Palmfeldt J, Olsen LH, Frøkiær J, Jørgensen TM: Epidermal growth factor and monocyte chemotactic peptide-1: Potential biomarkers of urinary tract obstruction in children with hydronephrosis. J Pediatr Urol 2012, S1477, 285–289.
  4. Rodhe N, Löfgren S, Strindhall J, Matussek A, Mölstad S: Cytokines in urine in elderly subjects with acute cystitis and asymptomatic bacteriuria. Scand J Prim Health Care 2009, 27, 74–79.
  5. Segerer S, Alpers CE: Chemokines and chemokine receptors in renal pathology. Curr Opin Nephrol Hypertens 2003, 12, 243–249.
  6. Kassir K, Vargas-Shiraishi O, Zaldivar F, Berman M, Singh J, Arrieta A: Cytokine profiles of pediatric patients treated with antibiotics for pyelonephritis: potential therapeutic impact. Clin Diagn Lab Immunol 2001, 8, 1060–1063.
  7. Lerner GR: Urinary tract infections in children. Pediatr Ann 1994, 23, 463, 466–473.
  8. Hertting O, Khalil A, Jaremko G, Chromek M, Li YH, Bakhiet M, Bartfai T, Tullus K, Brauner A: Enhanced chemokine response in experimental acute Escherichia coli pyelonephritis in IL-1beta-deficient mice. Clin Exp Immunol 2003, 131, 225–233.
  9. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990, 265, 621–636.
  10. Tramma D, Hatzistylianou M, Gerasimou G, Lafazanis V: Interleukin-6 and interleukin-8 levels in the urine of children with renal scarring. Pediatr Nephrol 2012, 27, 1525–1530.
  11. Augustyniak D, Majkowska-Skrobek G, Basiewicz-Worsztynowicz B, Jankowski A: The role of IL-6/sIL-6R complex and its natural inhibitor sgp130 in modulation of inflammatory process. Post Biochem 2006, 52, 194–203.
  12. Baggiolini M: Chemokines in pathology and medicine. J Intern Med 2001, 250, 91–104.
  13. Segerer S, Nelson PJ: Chemokines in renal diseases. Scientific World Journal 2005, 29, 835–844.
  14. Mak RH: Chronic kidney disease in children: state of the art. Pediatr Nephrol 2007, 22, 1687–1688.
  15. Jackson JA, Kim EJ, Begley B, Cheeseman J, Harden T, Perez SD, Thomas S, Warshaw B, Kirk AD: Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant 2011, 11, 2228–2234.
  16. Chen HL, Hung CH, Tseng HI, Yang RC, Chen HL, Hung CH, Tseng HI, Yang RC: Plasma IP-10 as a predictor of serious bacterial infection in infants less than 4 months of age. J Trop Pediatr 2011, 57, 145–151.
  17. Wada T, Furuichi K, Segawa-Takaeda C, Shimizu M, Sakai N, Takeda SI, Takasawa K, Kida H, Kobayashi KI, Mukaida N, Ohmoto Y, Matsushima K, Yokoyama H: MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 1999, 56, 995–1003.
  18. Kanmaz T, Feng P, Torrealba J, Kwun J, Fechner JH, Schultz JM, Dong Y, Kim HT, Dar W, Hamawy M, Knechtle S, Hu H: Surveillance of acute rejection in baboon renal transplantation by elevation of interferongamma inducible protein-10 and monokine induced by interferon-gamma in urine. Transplantation 2004, 78, 1002–1007.
  19. Edmonson MB, Wald ER: Treatment of pyelonephritis and risk of renal scarring. Pediatrics 2009, 123, 544–555.
  20. American Academy of Pediatrics. Committee on Quality Improvement, Subcommittee on Urinary Tract Infection Practice Parameter: The Diagnosis, Treatment, and Evaluation of the Initial Urinary Tract Infection in Febrile Infants and Young Children. Pediatrics 1999, 103, 843–852.
  21. Jantausch BA, O’Donnell R, Wiedermann BL: Urinary interleukin-6 and interleukin-8 in children with urinary tract infection. Pediatr Nephrol 2000, 15, 236–240.
  22. Olszyna D, Prins J, Dekkers P, De Jonge E, Speelman P, Van Deventer S, Van Der Poll T: Sequential measurements of chemokines in urosepsis and experimental endotoxemia. J Clin Immunol 1999, 19, 399–405.
  23. Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C, Bradwin G, Matsouaka R, Betensky RA, Curhan GC, Bonventre JV: Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 2008, 1, 200–208.
  24. Otto G, Burdick M, Strieter R, Godaly G: Chemokine response to febrile urinary tract infection. Kidney Int 2005, 68, 62–70.
  25. Godaly G, Otto G, Burdick MD, Strieter RM, Svanborg C: Fimbrial lectins influence the chemokine repertoire in the urinary tract mucosa. Kidney Int 2007, 71, 778–786.
  26. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ: Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science 1993, 260, 355–358.
  27. Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, Matsushima K, Kelvin DJ, Oppenheim JJ: Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 1993, 177, 1809–1814.
  28. Basiewicz-Worsztynowicz B, Karnas-Kalemba W, Augustyniak D, Polańska B, Jankowski A: The usefulness of chemikines RANTES and MIP-1alpha and elastaze in diagnostic process of respiratory tract infections in children. Adv Clin Exp Med 2005, 14, 523–529.